Carboplatin Injection shortage
Current 35 presentations · 9 manufacturers · first FDA posting Apr 28, 2023 · last update Oct 15, 2026
Manufacturers: Accord Healthcare Inc., Avyxa Pharma, LLC, Eugia US LLC, Fresenius Kabi USA, LLC, Gland Pharma Limited, Hospira, Inc., a Pfizer Company, Ingenus Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., Teyro Labs
Stated reasons (per FDA): Delay in shipping of the drug; Demand increase for the drug; Discontinuation of the manufacture of the drug; Other; Requirements related to complying with good manufacturing practices
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | Accord Healthcare Inc. | Current Unavailable |
Requirements related to complying with good manufacturing practices | Estimated recovery: TBD/ NDC non-Exempt | Posted Apr 28, 2023 Updated Oct 3, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | Accord Healthcare Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Estimated recovery: TBD/ NDC non-Exempt | Posted Apr 28, 2023 Updated Oct 3, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | Accord Healthcare Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Estimated recovery: TBD/ NDC non-Exempt | Posted Apr 28, 2023 Updated Oct 3, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | Accord Healthcare Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Estimated recovery: TBD/ NDC non-Exempt | Posted Apr 28, 2023 Updated Oct 3, 2026 |
| Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) | Avyxa Pharma, LLC | Current Available |
— | Posted Apr 28, 2023 Updated Sep 1, 2026 | |
| Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) | Avyxa Pharma, LLC | Current Available |
— | Posted Apr 28, 2023 Updated Sep 1, 2026 | |
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Eugia US LLC | Current Unavailable |
Demand increase for the drug | On backorder. Recovery: late October 2026. Check wholesalers for inventory | Posted Apr 28, 2023 Updated Oct 2, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Eugia US LLC | Current Available |
— | Check wholesalers for inventory | Posted Apr 28, 2023 Updated Oct 2, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | Fresenius Kabi USA, LLC | Current Unavailable |
Delay in shipping of the drug | Next release November 2026. Check wholesalers for inventory. | Posted Apr 28, 2023 Updated Oct 6, 2026 |
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | Gland Pharma Limited | Current Unavailable |
Discontinuation of the manufacture of the drug | Discontinued; Distributed by BPI Labs, LLC | Posted Apr 28, 2023 Updated Sep 15, 2026 |
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Gland Pharma Limited | Current Available |
— | Distributed by BPI Labs, LLC | Posted Apr 28, 2023 Updated Sep 15, 2026 |
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | Gland Pharma Limited | Current Limited Availability |
Demand increase for the drug | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Posted Apr 28, 2023 Updated Sep 15, 2026 |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | Gland Pharma Limited | Current Limited Availability |
Demand increase for the drug | Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC | Posted Apr 28, 2023 Updated Sep 15, 2026 |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | Hospira, Inc., a Pfizer Company | Current Unavailable |
Other | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | Hospira, Inc., a Pfizer Company | Current Unavailable |
Other | Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) | Hospira, Inc., a Pfizer Company | Current Limited Availability |
Demand increase for the drug | Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027 | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) | Hospira, Inc., a Pfizer Company | Current Limited Availability |
Other | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) | Hospira, Inc., a Pfizer Company | Current Limited Availability |
Demand increase for the drug | Limited Supply Available. Next Delivery and Estimated Recovery: December 2026 | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) | Hospira, Inc., a Pfizer Company | Current Limited Availability |
Other | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | Hospira, Inc., a Pfizer Company | Current Unavailable |
Other | Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | Hospira, Inc., a Pfizer Company | Current Unavailable |
Other | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Posted Apr 28, 2023 Updated Oct 8, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) | Teva Pharmaceuticals USA, Inc. | Current Limited Availability |
Other | Estimated recovery: December 2028 | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | Teva Pharmaceuticals USA, Inc. | Current Unavailable |
Other | Estimated recovery: January 2027 | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | Teva Pharmaceuticals USA, Inc. | Current Limited Availability |
Other | Estimated recovery: September 2027 | Posted Apr 28, 2023 Updated Oct 1, 2026 |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) | Teva Pharmaceuticals USA, Inc. | Current Limited Availability |
Other | Estimated recovery: February 2027 | Posted Apr 28, 2023 Updated Oct 1, 2026 |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Teyro Labs | Current Unavailable |
Discontinuation of the manufacture of the drug | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Teyro Labs | Current Unavailable |
Discontinuation of the manufacture of the drug | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Teyro Labs | Current Unavailable |
Discontinuation of the manufacture of the drug | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Teyro Labs | Current Unavailable |
Discontinuation of the manufacture of the drug | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Apr 28, 2023 Updated Oct 15, 2026 |
| Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | Ingenus Pharmaceuticals LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted Feb 20, 2026 Updated Feb 20, 2026 Discontinued Feb 20, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | Ingenus Pharmaceuticals LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted Feb 20, 2026 Updated Feb 20, 2026 Discontinued Feb 20, 2026 |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Teyro Labs | To Be Discontinued | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Jun 1, 2026 Updated Jun 1, 2026 Discontinued Jun 1, 2026 |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Teyro Labs | To Be Discontinued | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Jun 1, 2026 Updated Jun 1, 2026 Discontinued Jun 1, 2026 |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Teyro Labs | To Be Discontinued | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Jun 1, 2026 Updated Jun 1, 2026 Discontinued Jun 1, 2026 |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Teyro Labs | To Be Discontinued | — | Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug | Posted Jun 1, 2026 Updated Jun 1, 2026 Discontinued Jun 1, 2026 |